Ahmed Tawakol1, Parmanand Singh2, Marina Mojena2, María Pimentel-Santillana2, Hamed Emami2, Megan MacNabb2, James H F Rudd2, Jagat Narula2, José A Enriquez2, Paqui G Través2, María Fernández-Velasco2, Ramón Bartrons2, Paloma Martín-Sanz2, Zahi A Fayad2, Alberto Tejedor2, Lisardo Boscá1. 1. From the Cardiology Division, Massachusetts General Hospital and Harvard Medical School, Boston (A.T., P.S., H.E., M.M.); Cardiology Division, Weill Cornell Medical College, New York Presbyterian Hospital, NY (P.S.); Instituto de Investigaciones Biomédicas 'Alberto Sols' (CSIC-UAM), Madrid, Spain (M.M., M.P.-S., P.G.T., M.F.-V., P.M.-S., L.B.); Centro de Investigación en Red en Enfermedades Hepáticas y Digestivas (CIBERHED), Instituto de Salud Carlos III, Madrid, Spain (M.M., M.P.-S., P.G.T., M.F.-V., P.M.-S., L.B.); Hospital General Universitario Gregorio Marañón, Madrid, Spain (M.M., A.T.); Division of Cardiovascular Medicine, University of Cambridge, Cambridge, United Kingdom (J.H.F.R.); Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY (J.N., Z.A.F.); Centro Nacional de Investigaciones Cardiovasculares, Melchor Fernández Almagro, Madrid, Spain (J.A.E.); The Salk Institute for Biological Studies, La Jolla, CA (P.G.T.); Idipaz, Hospital Universitario La Paz, Madrid, Spain (M.F.-V.); and Unitat de Bioquímica i Biologia Molecular, Departament de Ciències Fisiològiques II, Universitat de Barcelona, Barcelona, Spain (R.B.). atawakol@partners.org lbosca@iib.uam.es. 2. From the Cardiology Division, Massachusetts General Hospital and Harvard Medical School, Boston (A.T., P.S., H.E., M.M.); Cardiology Division, Weill Cornell Medical College, New York Presbyterian Hospital, NY (P.S.); Instituto de Investigaciones Biomédicas 'Alberto Sols' (CSIC-UAM), Madrid, Spain (M.M., M.P.-S., P.G.T., M.F.-V., P.M.-S., L.B.); Centro de Investigación en Red en Enfermedades Hepáticas y Digestivas (CIBERHED), Instituto de Salud Carlos III, Madrid, Spain (M.M., M.P.-S., P.G.T., M.F.-V., P.M.-S., L.B.); Hospital General Universitario Gregorio Marañón, Madrid, Spain (M.M., A.T.); Division of Cardiovascular Medicine, University of Cambridge, Cambridge, United Kingdom (J.H.F.R.); Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY (J.N., Z.A.F.); Centro Nacional de Investigaciones Cardiovasculares, Melchor Fernández Almagro, Madrid, Spain (J.A.E.); The Salk Institute for Biological Studies, La Jolla, CA (P.G.T.); Idipaz, Hospital Universitario La Paz, Madrid, Spain (M.F.-V.); and Unitat de Bioquímica i Biologia Molecular, Departament de Ciències Fisiològiques II, Universitat de Barcelona, Barcelona, Spain (R.B.).
Abstract
OBJECTIVE: Although it is accepted that macrophage glycolysis is upregulated under hypoxic conditions, it is not known whether this is linked to a similar increase in macrophage proinflammatory activation and whether specific energy demands regulate cell viability in the atheromatous plaque. APPROACH AND RESULTS: We studied the interplay between macrophage energy metabolism, polarization, and viability in the context of atherosclerosis. Cultured human and murine macrophages and an in vivo murine model of atherosclerosis were used to evaluate the mechanisms underlying metabolic and inflammatory activity of macrophages in the different atherosclerotic conditions analyzed. We observed that macrophage energetics and inflammatory activation are closely and linearly related, resulting in dynamic calibration of glycolysis to keep pace with inflammatory activity. In addition, we show that macrophage glycolysis and proinflammatory activation mainly depend on hypoxia-inducible factor and on its impact on glucose uptake, and on the expression of hexokinase II and ubiquitous 6-phosphofructo-2-kinase. As a consequence, hypoxia potentiates inflammation and glycolysis mainly via these pathways. Moreover, when macrophages' ability to increase glycolysis through 6-phosphofructo-2-kinase is experimentally attenuated, cell viability is reduced if subjected to proinflammatory or hypoxic conditions, but unaffected under control conditions. In addition to this, granulocyte-macrophage colony-stimulating factor enhances anerobic glycolysis while exerting a mild proinflammatory activation. CONCLUSIONS: These findings, in human and murine cells and in an animal model, show that hypoxia potentiates macrophage glycolytic flux in concert with a proportional upregulation of proinflammatory activity, in a manner that is dependent on both hypoxia-inducible factor -1α and 6-phosphofructo-2-kinase.
OBJECTIVE: Although it is accepted that macrophage glycolysis is upregulated under hypoxic conditions, it is not known whether this is linked to a similar increase in macrophage proinflammatory activation and whether specific energy demands regulate cell viability in the atheromatous plaque. APPROACH AND RESULTS: We studied the interplay between macrophage energy metabolism, polarization, and viability in the context of atherosclerosis. Cultured human and murine macrophages and an in vivo murine model of atherosclerosis were used to evaluate the mechanisms underlying metabolic and inflammatory activity of macrophages in the different atherosclerotic conditions analyzed. We observed that macrophage energetics and inflammatory activation are closely and linearly related, resulting in dynamic calibration of glycolysis to keep pace with inflammatory activity. In addition, we show that macrophage glycolysis and proinflammatory activation mainly depend on hypoxia-inducible factor and on its impact on glucose uptake, and on the expression of hexokinase II and ubiquitous 6-phosphofructo-2-kinase. As a consequence, hypoxia potentiates inflammation and glycolysis mainly via these pathways. Moreover, when macrophages' ability to increase glycolysis through 6-phosphofructo-2-kinase is experimentally attenuated, cell viability is reduced if subjected to proinflammatory or hypoxic conditions, but unaffected under control conditions. In addition to this, granulocyte-macrophage colony-stimulating factor enhances anerobic glycolysis while exerting a mild proinflammatory activation. CONCLUSIONS: These findings, in human and murine cells and in an animal model, show that hypoxia potentiates macrophage glycolytic flux in concert with a proportional upregulation of proinflammatory activity, in a manner that is dependent on both hypoxia-inducible factor -1α and 6-phosphofructo-2-kinase.
Authors: Julie M Roda; Laura A Sumner; Randall Evans; Gary S Phillips; Clay B Marsh; Timothy D Eubank Journal: J Immunol Date: 2011-07-15 Impact factor: 5.422
Authors: Paqui G Través; Pedro de Atauri; Silvia Marín; María Pimentel-Santillana; Juan-Carlos Rodríguez-Prados; Igor Marín de Mas; Vitaly A Selivanov; Paloma Martín-Sanz; Lisardo Boscá; Marta Cascante Journal: J Immunol Date: 2011-12-21 Impact factor: 5.422
Authors: Luai Huleihel; Jenna L Dziki; Joseph G Bartolacci; Theresa Rausch; Michelle E Scarritt; Madeline C Cramer; Tatiana Vorobyov; Samuel T LoPresti; Ilea T Swineheart; Lisa J White; Bryan N Brown; Stephen F Badylak Journal: Semin Immunol Date: 2017-07-21 Impact factor: 11.130
Authors: Ziad S Mahmassani; Paul T Reidy; Alec I McKenzie; Chris Stubben; Michael T Howard; Micah J Drummond Journal: J Appl Physiol (1985) Date: 2019-02-14
Authors: Ahmed Tawakol; Amorina Ishai; Danny Li; Richard A P Takx; Sophia Hur; Yannick Kaiser; Miguel Pampaloni; Adam Rupert; Denise Hsu; Irini Sereti; Rémi Fromentin; Nicolas Chomont; Peter Ganz; Steven G Deeks; Priscilla Y Hsue Journal: JAMA Cardiol Date: 2017-02-01 Impact factor: 14.676
Authors: Nina E Murugina; Anna S Budikhina; Yulia A Dagil; Polina V Maximchik; Lyudmila S Balyasova; Vladimir V Murugin; Mikhail V Melnikov; Viktoriya S Sharova; Anna M Nikolaeva; Georgy Z Chkadua; Boris V Pinegin; Mikhail V Pashenkov Journal: J Biol Chem Date: 2020-01-31 Impact factor: 5.157
Authors: Hweixian Leong Penny; Je Lin Sieow; Giulia Adriani; Wei Hseun Yeap; Peter See Chi Ee; Boris San Luis; Bernett Lee; Terence Lee; Shi Ya Mak; Ying Swan Ho; Kong Peng Lam; Choon Kiat Ong; Ruby Y J Huang; Florent Ginhoux; Olaf Rotzschke; Roger D Kamm; Siew Cheng Wong Journal: Oncoimmunology Date: 2016-06-21 Impact factor: 8.110